Anti-VCAM-1 Ameliorates the Exacerbated Neuroinflammation Response and Improves Function Recovery [TCP2.1][JH2.2][HJT2.3][PTC2.4]in Diet-Induced Obese Mice After Stroke

Following stroke, animals were administered either 9 mg/kg of VCAM-1 or control treatment and then assessed on common motor behavior tasks prior to and 1-, 3-, 7-, 14-, and 28 days post-stroke. Additionally, we measured infarct volume (Neun) and macrophage/microglia and astrocyte coverage at acute and chronic timepoints (3- and 29 days) post-stroke. We confirmed after the amelioration of increasedVCAM-1 HFD-fed animals demonstrated improved functional recovery as well as reduced macrophage/microglia and astrocyte coverage, and prevented the increase in infarct expansion compared to HFD-fed animals given the control treatment.

Considering the limited treatment options available and the high rates of people with obesity to have a stroke, 𝛼VCAM-1 may serve as a potential intervention for reducing infarct expansion, neuroinflammation, and improve functional recovery.